Table 3.

Hospitalization/inpatient treatment

	TNF inhibitor naive patients (n = 1,468)			TNF inhibitor continuing patients (n = 733)
	Adalimumab (n = 669)	Etanercept (n = 628)	Infliximab (n = 171)	Adalimumab (n = 248)	Etanercept (n = 367)	Infliximab (n = 118)
Numbers of patients with at least hospitalization for any reason (%)	522	498	126	190	278	86
	78.03%	79.30%	73.68%	76.61%	75.75%	72.88%
Numbers of patients with hospitalization related to RA	298	290	66	95	162	47
	44.54%	46.18%	38.60%	38.31%	44.14%	39.83%